OCUP / Does Ocuphire Pharma, Inc. (OCUP) Have the Potential to Rally 323.89% as Wall Street Analysts Expect?

Viatris Inc. VTRS, and Ocuphire Pharma Inc. OCUP, +3.08% said Wednesday that the U.S. Food and Drug Administration has approved Ryzumvi to treat the s more_horizontal

Ocuphire Pharma Inc OCUP was plunging over 22% at one point on Friday after the company announced it appointed Rick Rodgers to the role of interim CE more_horizontal

The consensus price target hints at a 257.1% upside potential for Ocuphire Pharma, Inc. (OCUP). While empirical research shows that this sought-after more_horizontal

Ocuphire Pharma, Inc. (OCUP) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit fro more_horizontal

The mean of analysts' price targets for Ocuphire Pharma, Inc. (OCUP) points to a 323.9% upside in the stock. While this highly sought-after metric has more_horizontal

Ocuphire Pharma, Inc. (OCUP) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound more_horizontal

Ocuphire Pharma (NASDAQ: OCUP ) stock is falling on Thursday after the company posted results from a Phase 2 clinical trial. The clinical trial evalua more_horizontal

FARMINGTON HILLS, Mich., April 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical compan more_horizontal